ArticlePloS one2017
HEK293T cell lines defective for O-linked glycosylation.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Design rules for bioorthogonal glycan-based tools.The Biochemical journal · 2026Review
- Cell culture medium influences RSV G protein glycosylation and recognition by monoclonal antibodies.Virology journal · 2026Article
- A Synergistic Inhibitor Development Strategy Against Human UDP-Galactose-4-Epimerase.Angewandte Chemie (International ed. in English) · 2026Article
- Cell Engineering for Increasing Production of Recombinant Proteins in Mammalian Cells.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
- Dual Synthetic Pathways for Organotin-Functionalized Mesoporous Silica Nanoparticles: Targeted Therapeutic Platforms with Folic Acid and PEI Formulation.Nanomaterials (Basel, Switzerland) · 2025Article
- MFSD6 is an entry receptor for enterovirus D68.Nature · 2025Article
- Article
- Analysis of Glycosylation and Disulfide Bonding of Wild-Type SARS-CoV-2 Spike Glycoprotein.Journal of virology · 2022Article
- Article
- Analysis of glycosylation and disulfide bonding of wild-type SARS-CoV-2 spike glycoprotein.bioRxiv : the preprint server for biology · 2021Article
- Glycoengineering of AAV-delivered monoclonal antibodies yields increased ADCC activity.Molecular therapy. Methods & clinical development · 2021Article
- An enzymatic toolkit for selective proteolysis, detection, and visualization of mucin-domain glycoproteins.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Bump-and-Hole Engineering Identifies Specific Substrates of Glycosyltransferases in Living Cells.Molecular cell · 2020Article
- Discovery of O-Linked Carbohydrate on HIV-1 Envelope and Its Role in Shielding against One Category of Broadly Neutralizing Antibodies.Cell reports · 2020Article
- Human UDP-galactose 4'-epimerase (GALE) is required for cell-surface glycome structure and function.The Journal of biological chemistry · 2020Article
- An Atlas of Human Glycosylation Pathways Enables Display of the Human Glycome by Gene Engineered Cells.Molecular cell · 2019Article
- Human Immunodeficiency Virus and Simian Immunodeficiency Virus Maintain High Levels of Infectivity in the Complete Absence of Mucin-Type O-Glycosylation.Journal of virology · 2017Article
- An efficient system for bioconjugation based on a widely applicable engineered O-glycosylation tag.mAbsArticle
- Genetic glycoengineering in mammalian cells.The Journal of biological chemistryReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Here we describe derivatives of the HEK293T cell line that are defective in their ability to generate mucin-type O-linked glycosylation. Using CRISPR/Cas9 and a single-cell GFP-sorting procedure, the UDP-galactose-4-epimerase (GALE), galactokinase 1 (GALK1), and galactokinase 2 (GALK2) genes were knocked out individually and in combinations with greater than 90% of recovered clones having the desired mutations. Although HEK293T cells are tetraploid, we found this approach to be an efficient method to target and disrupt all 4 copies of the target gene. Deficient glycosylation in the GALE knockout cell line could be rescued by the addition of galactose and N-acetylgalactosamine (GalNAc) to the cell culture media. However, when key enzymes of the galactose/GalNAc salvage pathways were disrupted in tandem (GALE+GALK1 or GALE+GALK2), O-glycosylation was eliminated and could not be rescued by the addition of either galactose plus GalNAc or UDP-galactose plus UDP-GalNAc. GALK1 and GALK2 are key enzymes of the galactose/GalNAc salvage pathways. Mass spectrometry was performed on whole cell lysate of the knockout cell lines to verify the glycosylation phenotype. As expected, the GALE knockout was almost completely devoid of all O-glycosylation, with minimal glycosylation as a result of functional salvage pathways. However, the GALE+GALK1 and GALE+GALK2 knockout lines were devoid of all O-glycans. Mass spectrometry analysis revealed that the disruption of GALE, GALK1, and GALE+GALK2 had little effect on the N-glycome. But when GALE was knocked out in tandem with GALK1, N-glycans were exclusively of the high mannose type. Due to the well-characterized nature of these five knockout cell lines, they will likely prove useful for a wide variety of applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.